| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49ff31b29d3aeba7df1a175387e80237 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-9066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-63 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-9066 |
| filingDate |
2019-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e7a1a9ab7248d693efeb9fbc6f3dac1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_085361c6b6329b064a5052b01d1c181c |
| publicationDate |
2020-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020054597-A1 |
| titleOfInvention |
Inhibited expression of pd-l1 and enhanced expression of pd-1 |
| abstract |
Processes for treating an autoimmune disease or condition by decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject. |
| priorityDate |
2017-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |